泰利塔西塞普特加低剂量mycophenolate mofetil用于治疗IgA脏病的治疗:一个回顾性研究
Huapan Shu1, Yujuan Wang1, Xiaoqing Li1
1Department of Nephrology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, 430060, Hubei, China.
Clinical and experimental medicine
|August 11, 2025
概括
这项研究表明,与mycophenolate mofetil (MMF) 结合使用telitacicept,可显著降低免疫球蛋白A腎病 (IgAN) 患者的蛋白尿和血尿. 治疗组合维持了稳定的功能,没有副作用.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫球蛋白A脏病 (IgAN) 目前缺乏特定的向疗法.
- 氨酸莫菲蒂尔 (MMF) 在中国Igan患者中显示出有效性.
- 一种TACI-FC融合蛋白的Telitacicept针对B细胞的成熟和激活,在II阶段IgAN试验中证明了益处.
研究的目的:
- 评估telitacicept与低剂量MMF结合治疗Igan的疗效和安全性.
- 评估对蛋白尿的影响,估计的淋巴细胞过率 (eGFR) 和血.
主要方法:
- 一项回顾性队列研究,涉及24名Igan患者,接受了telelitacicept加MMF治疗.
- 主要结局:蛋白尿和eGFR的变化.
- 二次结局:血液流动的变化.
- 平均随访时间为23个月.
主要成果:
- 在多个时间点观察到蛋白尿的显著减少,治疗后长达24个月 (p < 0.0122).
- 所有患者在整个随访期间都保持了稳定的eGFR.
- 泰利塔cept加MMF治疗导致出血症的显著缓解.
- 没有报告任何不良副作用.
结论:
- 与低剂量MMF结合使用Telitacicept为Igan提供了一个有前途的治疗策略.
- 这种组合疗法在临床上显著地减少了蛋白尿和血尿.
- 该治疗方案在IGAN患者中显示出良好的安全性和稳定的功能.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
232
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
232
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237
Dipeptidyl Peptidase 4 Inhibitors
257
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
257
Nephrotic Syndrome II : Assessment and Medical Management
21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21


